PeptiDream Inc
TSE:4587

Watchlist Manager
PeptiDream Inc Logo
PeptiDream Inc
TSE:4587
Watchlist
Price: 2 738 JPY 6.81% Market Closed
Market Cap: 354.9B JPY
Have any thoughts about
PeptiDream Inc?
Write Note

PeptiDream Inc
Unrealized Security Profit/Loss

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PeptiDream Inc
Unrealized Security Profit/Loss Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Unrealized Security Profit/Loss CAGR 3Y CAGR 5Y CAGR 10Y
PeptiDream Inc
TSE:4587
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takara Bio Inc
TSE:4974
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharma Foods International Co Ltd
TSE:2929
Unrealized Security Profit/Loss
ÂĄ566m
CAGR 3-Years
314%
CAGR 5-Years
127%
CAGR 10-Years
17%
S
StemRIM Inc
TSE:4599
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PeptiDream Inc
Glance View

Market Cap
354.9B JPY
Industry
Biotechnology

PeptiDream Inc. engages in the biopharmaceutical business that includes research and development of non standard peptide therapeutics. The company is headquartered in Kawasaki-Shi, Kanagawa-Ken and currently employs 141 full-time employees. The company went IPO on 2013-06-11. The firm operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The firm is involved in the business centered on drug development based on special peptides. The firm's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).

Intrinsic Value
2 322.19 JPY
Overvaluation 15%
Intrinsic Value
Price

See Also

Back to Top